OneSource Specialty Pharma Limited (NSE: ONESOURCE) announced today that it has received the Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (USFDA) for its Sterile Product Division (SPD) facility in Bengaluru, with a ‘Voluntary Action Indicated’ (VAI) classification. This follows an inspection conducted from June 22 to June 30, 2026. This development highlights the company’s commitment to maintaining high standards of quality, regulatory compliance, and operational excellence.

Regulatory Milestone

The EIR with VAI classification signifies a regulatory milestone for OneSource. Neeraj Sharma, Managing Director & CEO, commented, “We are pleased to receive the EIR with VAI classification from the USFDA for our SPD facility. This outcome reflects our continued dedication to quality and compliance across our operations.”

Strategic Importance

The SPD facility plays a crucial role in OneSource’s sterile manufacturing capabilities, enabling the company to support the evolving needs of its global partners. This achievement adds to OneSource’s robust regulatory track record as it continues to build a globally competitive CDMO platform.

Future Outlook

As OneSource advances its capabilities in drug-device combinations, biologics, sterile injectables, and soft gelatin capsules, this milestone positions the company for continued growth and success in the pharmaceutical manufacturing sector. The company remains focused on delivering efficient, end-to-end solutions to its global clientele.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Onesource Specialty Pharma Limited

Onesource Specialty Pharma Limited belongs to the Healthcare › Biotechnology sector. Here’s a quick read on where the business and the stock stand today.

Onesource falls 14.8% over three months and has not found a floor yet. Razor-thin margins below 5% make profitability extremely vulnerable — this business needs scale or pricing power urgently. No meaningful dividend — total return is entirely dependent on capital appreciation. RSI stands at 30, well into oversold territory. Yet sellers still dominated on 17 of recent sessions versus 13 for buyers, so the pressure has not fully lifted. Revenue grows at 232.4% yet the PEG reaches 99.00 — expensive for that growth. Furthermore, the stock drops 14.8% in three months. Neither value nor momentum supports this setup. It needs an earnings beat or a price reset first. Check Fundamentals of Onesource Specialty Pharma Limited.

Hikal Limited (NSE: HIKAL) announced today that Swissmedic, the Swiss Agency for Therapeutic Products, has granted a Certificate of GMP Compliance to its active pharmaceutical ingredient (API) facility in Bengaluru. This certification confirms the facility’s adherence to Good Manufacturing Practice (GMP) requirements under the Mutual Recognition Agreement between the European Union and Switzerland. The certification follows successful inspections by Brazil’s ANVISA and Japan’s PMDA, reinforcing the site’s standing with leading global regulators.

Enhanced Global Regulatory Standing

The Swissmedic certification strengthens Hikal’s global regulatory standing and expands access to European and other regulated markets. This development is a significant step in the company’s strategy to diversify its geographic footprint in the pharmaceutical business, building resilience against geopolitical and trade uncertainties.

Strategic Importance

Commenting on the development, Mr. Sameer Hiremath, Chairman & Managing Director of Hikal Limited, stated: ‘The Swissmedic certification is a strong endorsement of the quality systems at our Bengaluru facility. It is an important step in expanding the global reach of our pharmaceutical business and opens new opportunities with customers in Europe and other regulated markets. Quality, compliance, and manufacturing excellence remain the foundation of our long-term customer partnerships.’ This recognition is part of Hikal’s broader strategy to enhance its global presence and cater to a wider customer base across regulated markets.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Hikal Limited

Hikal Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Hikal holds in the upper half of its 52-week range, a sign the market backs the stock. Razor-thin margins below 5% make profitability extremely vulnerable — this business needs scale or pricing power urgently. 4 loss quarters over five years is a serious red flag — earnings quality is poor and recovery is not guaranteed. The stock holds at 60% of its 52-week range with RSI at 48. In other words, neither side has a clear edge right now. The stock holds up despite -5.4% revenue growth and a PEG of 99.00. That could signal an early turnaround. Alternatively, index flows simply support the price. Watch whether analysts revise estimates upward — that is the real signal. Check Fundamentals of Hikal Limited.

Sun Pharmaceutical Industries Limited (SUNPHARMA) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for ILUMYA® (tildrakizumab-asmn) for the treatment of adults with active psoriatic arthritis (PsA). This approval marks a significant milestone for Sun Pharma, expanding the use of ILUMYA beyond moderate-to-severe plaque psoriasis.

Expanding Therapeutic Reach

ILUMYA, an IL-23 inhibitor, is now an option for adults with active psoriatic arthritis who require healthcare provider-administered treatment. This approval is supported by Phase 3 INSPIRE-1 and INSPIRE-2 clinical studies, which demonstrated the efficacy and safety of ILUMYA after two doses at 24 weeks in adult patients with active psoriatic arthritis.

Clinical Insights and Safety

The safety data in the studies were consistent with the well-documented safety profile of ILUMYA. No new safety signals were identified. However, ILUMYA may increase the risk of infection, and patients should be evaluated for tuberculosis (TB) infection prior to initiating treatment. The most common adverse reactions include upper respiratory infections, injection site reactions, and diarrhea for plaque psoriasis, and upper respiratory tract infections and COVID-19 for psoriatic arthritis.

This approval underscores Sun Pharma’s commitment to addressing complex chronic diseases and providing innovative therapeutic options for patients. With this milestone, Sun Pharma continues to strengthen its portfolio in psoriatic disease, offering hope and improved management for millions affected by these conditions.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Sun Pharmaceutical Industries Limited

Sun Pharmaceutical Industries Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Sun falls 9.0% over three months and has not found a floor yet. The PEG reaches 3.29. The stock trades on brand and index weight, not on growth. Premium net margins of 20.2% demonstrate strong cost discipline and a wide competitive moat. The stock holds at 38% of its 52-week range with RSI at 37. In other words, neither side has a clear edge right now. Revenue grows at 10.4% and profits at 10.6% CAGR, with D/E of 0.03. Meanwhile, the stock dips 9.0% in three months without any fundamental deterioration. Consequently, the stock quietly becomes cheaper relative to earnings power. For long-term investors, that is a feature. Check Fundamentals of Sun Pharmaceutical Industries Limited.